↓ Skip to main content

microRNAs Make the Call in Cancer Personalized Medicine

Overview of attention for article published in Frontiers in Cell and Developmental Biology, September 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
1 news outlet
twitter
5 X users

Readers on

mendeley
131 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
microRNAs Make the Call in Cancer Personalized Medicine
Published in
Frontiers in Cell and Developmental Biology, September 2017
DOI 10.3389/fcell.2017.00086
Pubmed ID
Authors

Simone Detassis, Margherita Grasso, Valerio Del Vescovo, Michela A. Denti

Abstract

Since their discovery and the advent of RNA interference, microRNAs have drawn enormous attention because of their ubiquitous involvement in cellular pathways from life to death, from metabolism to communication. It is also widely accepted that they possess an undeniable role in cancer both as tumor suppressors and tumor promoters modulating cell proliferation and migration, epithelial-mesenchymal transition and tumor cell invasion and metastasis. Moreover, microRNAs can even affect the tumor surrounding environment influencing angiogenesis and immune system activation and recruitment. The tight association of microRNAs with several cancer-related processes makes them undoubtedly connected to the effect of specific cancer drugs inducing either resistance or sensitization. In this context, personalized medicine through microRNAs arose recently with the discovery of single nucleotide polymorphisms in the target binding sites, in the sequence of the microRNA itself or in microRNA biogenesis related genes, increasing risk, susceptibility and progression of multiple types of cancer in different sets of the population. The depicted scenario implies that the overall variation displayed by these small non-coding RNAs have an impact on patient-specific pharmacokinetics and pharmacodynamics of cancer drugs, pushing on a rising need of personalized treatment. Indeed, microRNAs from either tissues or liquid biopsies are also extensively studied as valuable biomarkers for disease early recognition, progression and prognosis. Despite microRNAs being intensively studied in recent years, a comprehensive review describing these topics all in one is missing. Here we report an up-to-date and critical summary of microRNAs as tools for better understanding personalized cancer biogenesis, evolution, diagnosis and treatment.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 131 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 131 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 19 15%
Student > Ph. D. Student 18 14%
Researcher 17 13%
Student > Master 13 10%
Student > Doctoral Student 12 9%
Other 18 14%
Unknown 34 26%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 39 30%
Medicine and Dentistry 18 14%
Agricultural and Biological Sciences 9 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Immunology and Microbiology 5 4%
Other 15 11%
Unknown 39 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2023.
All research outputs
#2,754,999
of 23,578,918 outputs
Outputs from Frontiers in Cell and Developmental Biology
#510
of 9,453 outputs
Outputs of similar age
#52,413
of 319,374 outputs
Outputs of similar age from Frontiers in Cell and Developmental Biology
#3
of 25 outputs
Altmetric has tracked 23,578,918 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,453 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,374 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.